Medivir hopes for 4th time lucky with latest CEO
To view this email as a web page, click here

Today's Rundown

Featured Story

EMA starts rolling review of Merck's molnupiravir, continuing rapid regulatory response to COVID-19 antiviral data

Merck has opened another front in its campaign to get molnupiravir to market, kicking off a process that could lead to the approval of the oral COVID-19 antiviral in the European Union.

read more

Top Stories

Erytech shifts focus to leukemia as lead drug flunks late-stage pancreatic cancer trial

After seeing an overall survival benefit in a mid-stage study of eryaspase in pancreatic cancer, Erytech Pharma likely thought a phase 3 would be in the bag. But the results are out and the phase 3 trial did not confirm the earlier result.

read more

AstraZeneca veteran takes up CEO post at Medivir, becoming 4th person to hold the post in quick succession

And the next person to hold the CEO post at Medivir is … Jens Lindberg. The AstraZeneca veteran will become the fourth person to hold the post, on an interim or permanent basis, in quick succession when he takes up the position.

read more

Sponsored: New Wacker Biotech site in San Diego (CA) serves growing pDNA demand for cell & gene therapy

Plasmid DNA Manufacturing: New Wacker Biotech site in San Diego (CA) serves growing pDNA demand for cell & gene therapy. Learn more about our plug & play platform.

read more

Gilead's Immunomedics CMO jumps to Aadi as the biotech eagerly awaits FDA decision for first drug

She got Trodelvy to the finish line and now Loretta Itri, M.D., hopes to get Aadi Bioscience's first drug to market. The Immunomedics chief medical officer is leaving the Gilead-owned company to take up the same post at Aadi. 

read more

Cedilla tops off series B with additional $25M to test drugs in mesothelioma, certain breast cancers

Cedilla Therapeutics added $25 million to its 2020 series B to bring two lead programs into the clinic next year. One goes after mesothelioma and certain squamous cell carcinomas, and the other targets certain cancers such as breast, esophageal, stomach, ovarian and uterine.

read more

Juventas Cell Therapy closes a $63M funding round as it eyes a big push for blood cancer hopeful

Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19.

read more

Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report

Jefferies analysts examined new animal data that in vivo gene editing players Intellia and LogicBio presented at the European Society of Gene and Cell Therapy (ESGCT) conference and concluded that investors are still underestimating the potential of the emerging technology, which is designed to be injected directly into patients to correct inherited diseases.

read more

Alexa is finding a voice in healthcare. Cedars-Sinai, Boston Children's sign on for new Amazon smart hospital service

Amazon launched a new service for hospitals that will embed its voice technology deeper into clinical settings at scale. As part of Alexa Smart Properties, the service will simplify how hospitals deploy and manage Alexa-enabled devices. An Amazon executive said the new service is just the tip of the iceberg for using ambient technology in healthcare.

read more

With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and more

With its third multimillion-dollar influx of funding in barely a year, another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place.

read more

Top 10 drug launch disasters

An estimated 40% of drugs approved between 2004 and 2016 underperformed, according to Wall Street’s prelaunch sales forecasts. That's a lousy track record, given that a strong launch is critical to a drug's success. Here, we list 10 drug launches from the past five years that suffered the most noteworthy failures.

read more

Resources

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

Whitepaper: Create a seamless experience across eConsent, eCOA & more

Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper.

Research: eTMF Implementation Quick Guide

Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF.

Whitepaper: Modernizing Key Clinical Trial Processes with Artificial Intelligence

This whitepaper addresses where AI can make the biggest impact in clinical trials.

Free Infographic: Identifying Opportunities for Biotech Scale-Up

Looking to accelerate your biotech company, but not sure where to start?

Paid Marketplace: Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Whitepaper: Transform LIMS Data into Action-Ready Insights with Advanced Analytics

Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data.

Whitepaper: Clinical trial simulation: Advanced modeling techniques enable data-driven supply chain planning

Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies.

Whitepaper: Big Challenges for Small Sponsors: Competition in Oncology Research

Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events